Open Orphan Plc (GB:HVO) has released an update.
Open Orphan Plc, a leading contract research organization, has announced positive results from a Phase 2a RSV human challenge trial for Enanta Pharmaceuticals’ antiviral candidate EDP-323. The trial demonstrated the candidate’s safety, tolerability, and significant antiviral effect in reducing viral load and clinical symptoms in healthy adults. hVIVO’s expertise in human challenge trials continues to support the accelerated development of respiratory disease treatments.
For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.
